31 results about "Cardiac Muscle Contraction" patented technology

Devices for stabilizing tissue during a surgical procedure. The beating heart may be stabilized during a surgical procedure on the heart, using a described stabilizing device. In one example, a stabilizing device is introduced through an opening in the chest and brought into contact with the beating heart. By contacting the heart with the device and by exerting a stabilizing force on the device, the motion of the heart caused by the contraction of the heart muscles id effectively eliminated such that the heart is stabilized and the site of the surgery moves only minimally if at all.

The invention discloses an intelligent sleep monitoring system with a small contact surface. The intelligent sleep monitoring system consists of a physiological signal acquisition module, a micro control unit (MCU) control module, a power module, a sleeping posture adjustment module and an alarm and rescue module, wherein the physiological signal acquisition module balances the generated force due to myocardial contraction, chest contraction in the respiration process and other muscular movements in the lying process by adopting an air cushion, the body respiration, heart rate, displacement and other physiological signals are converted into electric signals through a pressure sensor, the electric signals are filtered and amplified and are transmitted to the MCU for processing and judging whether the abnormalities of sleep apnea, sudden cardiac arrest, drop and the like occur; when the abnormality is detected, the MCU drives a stepping motor, so that the pillow is deformed, the sleep respiration is adjusted, and corresponding audible and visual alarm is performed aiming at the abnormality. The contact area between the system and a measured body is small, a sensor is not required to be worn, the sleep is not influenced, the cost is low, and the operation, maintenance and management are convenient. The system can be used for a sleep monitoring system for performing daily household monitoring on young and old people.

A system and method for calculating the arterial compliance, stiffness, and arterial flow and resistance indices for any artery in issue of a subject having a blood pressure monitoring device configured to calculate systolic and diastolic blood pressure readings for an artery of the subject, a blood flow velocity monitoring device configured to calculate the velocity of blood flowing within the artery of the subject at a peak point of a systolic phase of contraction of the subject's heart muscle, peak-systolic velocity, and the velocity of blood flowing within the artery of the subject at an end point of a diastolic phase of the subject's heart muscle, end-diastolic velocity, and a central processing unit comprising a computer readable program embodied within the central processing unit configured to calculate the arterial compliance, stiffness, and arterial flow and resistance indices as a function of the area of the artery under initial systolic and end diastolic pressure, the area of the artery generating arterial elastic recoil pressure for continuous flow during the systolic and diastolic phases, peak-systolic and end-diastolic arterial flow velocities, and systolic and diastolic blood pressure.

The invention relates to the application of panaxoside Rh2, Ck and Rg3 to increase the heart contraction force, wherein the medicine compound comprises active panaxoside Rh2 and / or Ck and / or Rg3 and medicine carrier, to be made into injection, oral agent and film agent, to cure acute and low heart cardiac failure or reduced heart contraction force.

The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(aminoalkylene)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.

Method and apparatus for the non-invasive detection of certain breathing conditions, certain sleep disordered breathing conditions, or assessment of the person's myocardial contractility and its dynamic changes, comprising steps of: determining the sleep or wake status of a person, monitoring circulatory pulse waveforms and amplitude normalized pulse wave systolic upstrokes recorded from a person's body and determining at least one index of the upstroke to characterize the strength of the contraction of the heart during the systolic upstroke during a series of heart beats relating to a breathing cycle or an absent anticipated breathing cycle of the patient, and determining that a certain change in a breathing condition, a sleep disordered breathing condition, or assessment of the person's myocardial contractility and its dynamic changes, has occurred when a specific change in the sleep disordered breathing analysis, and the at least one index of the upstroke has been detected.

A system and method for managing and inhibiting cardiac remodeling in MI patients. Bi-ventricular stimulation is constantly provided with and without sensing to encourage normal pumping of the heart on a consistent basis. Pulses are administered using an anodal pulse followed by a cathodal pulse to stimulate cardiac muscle contraction. Stem cells are administered to MI areas to encourage regeneration of cardiac tissue in the damaged area. Stimulation may be provide to both healthy and compromised cardiac tissue.

A Chinese medicine for treating cardiac or cerebral ischemia is prepared from evodia fruit or rhubarb through immersing the evodia fruit in liquorice root solution for 2 hr, drying in air, pulverizing by 120 meshes and loading in capsules, or proportionally mixing rhubarb with bran, parching for 2 min, pulverizing by 120 meshes and loading in capsules. Its advantage is high curative effect.

The invention discloses an intelligent sleep monitoring system with a small contact surface, which is composed of a physiological signal acquisition module, an MCU control module, a power supply module, a sleeping posture adjustment module and an alarm rescue module. Among them, the physiological signal acquisition module uses an air cushion to balance the force generated by the myocardial contraction, chest contraction and other muscle movements during respiration, and converts physiological signals such as human respiration, heart rate, and displacement into electrical signals through pressure sensors. After filtering and amplifying, it is sent to the MCU for processing to determine whether there are abnormalities such as sleep apnea termination, cardiac arrest, and falling. sound and light alarm. The invention has a small contact area with the measured body, does not need to wear sensors, does not affect sleep, has low cost, and is convenient for operation and maintenance management. A sleep monitoring system that can be used for daily home monitoring of old and young.

The invention discloses application of compound 5-bromo-2-(alpha-hydroxy amyl) sodium benzoate (BZP) in medicine for curing cardiovascular disease, and belongs to the field of medicinal chemistry. Experiments prove that BZP has a protective effect for acute and chronic myocardial ischemia reperfusion injuries of a mouse, so that the overall animal acute myocardial infarction area is reduced through BZP oral administration and intravenous injection, the myocardial infarction area of the acute ischemia reperfusion injury of the isolated perfusion heart of the mouse is reduced through BZP, the function of myocardial contraction is improved, and the haematological myocardial injury markers are reduced; moreover, the invention also relates to application for delaying a process of the conversionfrom myocardial hypertrophy to cardiac failure after chronic orally taken administration of BZP for acute myocardial infarction of the mouse and reducing ventricular remodeling caused by ischemic heart disease of the mouse, the therapeutic action of the cardiac function is improved obviously; moreover, the invention also relates to the transient effect of the compound BZP for reducing the blood pressure of the hypertension mouse (SHR mouse), and these results indicate that the BZP has effective research and development prospects of myocardial damage protection medicine for clinically acute and chronic myocardial infarctions.

The present invention provides a health-preserving solid beverage beneficial for relieving hyperlipemia and hypertension. The health-preserving solid beverage is prepared by using cassia seeds, lotusleaves, haws, fiveleaf gynostemma herb, saffron crocus, dried tangerine peels, radix pueraiae and rhizoma curcumae longae, and combining stevioside and maltodextrin. A low-temperature extraction and concentration method maximally protects active ingredients in medicines from high-temperature damage; and spray-dried powder obtained by spray-drying is high in solubility. The combination of the several raw materials has overlay synergy in effects and is also complementary and balanced in mouthfeel. The health-preserving solid beverage has characteristics of portability, good mouthfeel, easy absorption, etc., is more easily received by consumers, particularly can be used as a health-preserving auxiliary for the hyperlipidemia and hypertension, can regulate qi and activate blood circulation, remove turbidity and relieve blood stasis, and prevent inflammation, oxidation and platelet aggregation, and has effects on inhibiting formation of atherosclerotic plaques, regulating lipoprotein metabolism, protecting vascular endothelium, increasing myocardial contractility, increasing cardiac output, expanding arterial vessels, etc.

The invention provides a composition for treating sheep placenta retention and a preparation method thereof, and relates to a medicament for treating sheep placenta retention. The composition is prepared by soaking the following raw materials with water and then decocting: angelica sinensis, the root of bidentate achyranthes, garden balsam, leonurus, sunflower plate, astragalus membranaceus, codonopsis pilosula, ligusticum wallichii, bighead atractylodes rhizome, as arum, rhizoma cyperi and liquorice. The composition is extensive in material source and low in cost, is convenient to use, is safe and effective, and has functions in enhancing contraction of uterine muscle and heart muscle, antibiosis and easing pain and enhancing resistance and immunity of human body.

The invention relates to an aortic counterpulsation balloon catheter capable of stepwise slow-release control. The aortic counterpulsation balloon catheter comprises a special-shaped balloon, a double-layer sheath and a Y-shaped joint. The special-shaped balloon is in the shape of a long strip and includes a plurality of sections of balloon bodies distributed in the length direction of the special-shaped balloon in sequence continuously and in a ball shape after inflation. One end of an outer tube of the double-layer sheath is connected to and communicates with the proximal end of the special-shaped balloon, the other end of the outer tube of the double-layer sheath is connected with the Y-shaped joint and communicates with one of connecting openings of the Y-shaped joint, one end of an inner tube of the double-layer sheath penetrates through the outer tube and the inside of the special-shaped balloon in turn and penetrates out through the distal end of the special-shaped balloon, anda flexible injection soft tip is arranged at the end of the inner tube, and the other end of the inner tube communicates with another connecting opening through the inside of the Y-shaped joint. The aortic counterpulsation balloon catheter has the advantages that when the balloon catheter is inflated and deflated, an interaction force can be generated through the non-synchronized phase differencebetween the distal and proximal ends of the inflation-deflation, the acting force can be used to provide greater kinetic energy, so that the energy load required by myocardial contraction is greatly reduced, and the auxiliary treatment effect is better.

The blood pressure lifting oral liquor is prepared with astragalus root, ophiopogon root, schisadra, angelica, licorice and cassia twig in certain proportion, and through mixing, grinding into powder, extraction in extracting tank with high alcohol content via soaking for 72 hr, filtering, and adding crystal sugar while stirring to dissolve and to form the blood pressure lifting oral liquor. The blood pressure lifting oral liquor has the functions of invigorating vital energy, raising blood pressure, stabilizing blood pressure, strengthening cardiac muscle contractility, resisting virus and promote blood circulation. It is used in treating hypotension and myocarditis, and has high effective rate and no toxic side effect.

The invention discloses isoquinolin compounds shown as formula I and salts thereof, wherein R1 represents H, -CH3 or Br. The invention also discloses a preparation method for the compounds, which comprises the step of reacting compounds shown as formula IV under the action of a reducing agent in an alcohol solvent. The invention also discloses a medicine composition containing the compounds, and application of the compounds to preparing medicines for treating arrhythmia. The isoquinolin compounds and the salts thereof have good antiarrhythmic activity and small function of inhibiting myocardial contraction force.

The invention relates to the technical field of functional food, in particular to a composition and a product for strengthening the heart and preventing cardiovascular diseases, and a preparation method of the product. The composition for strengthening the heart and preventing cardiovascular diseases comprises the following components in parts by weight: 12-20 parts of red lotus seeds, 2-10 partsof haws, 1-8 parts of raisins, 1-9 parts of Chinese wolfberries and 1-10 parts of fructus hippophae, wherein the raisins are selected from red raisins or purple raisins, and the composition further comprise at least one raw material selected from a group consisting of 1-7 parts of allium macrostemon, 0.5-3 parts of seville orange flowers, 0.5-4 parts of ginseng and 2-10 parts of red rice. The composition is mild in performance, does not cause internal heat after being eaten, and can enhance myocardial contractility, increase cardiac blood discharge, inhibit formation of thrombus in vivo, increase cardiac coronary flow and improve blood viscosity, so the composition can strengthen the heart and tonify qi, protect cardiovascular health and prevent cardiovascular diseases.

The invention discloses a flexible traveling wave driven heart micropump and a driving method thereof. The flexible traveling wave driven heart micropump comprises a pump body, a piezoelectric material, an elastic base body, a bionic three-flap valve, a two-flap valve, an inlet section and an outlet section, the piezoelectric materials are evenly disttendonuted on the two elastic base bodies, andthe two elastic base bodies are located on the upper wall face and the lower wall face of the pump body respectively. The two-flap valve is located at an inlet of the pump body, and the bionic three-flap valve is located at an outlet of the pump body. An electric signal with a phase difference is applied to the piezoelectric material, so that the elastic matrix drives the pump cavity to generate atraveling wave vibration mode, the volume change of the pump cavity and the opening and closing of the bionic three-flap valve and the bionic two-flap valve are caused, and blood in the cavity is pressed to directionally flow. During working, the shearing force between blood and the wall surface is low, hemolysis is avoided, no flow dead zone exists, the biocompatibility is good, and the high survival rate in the blood cell conveying process is guaranteed; cardiac contraction and diastole alternately is performed, and flow bionics is output; the driving part operates at extremely low noise, the speed controllability is good, and the blood supply requirements of patients under different organism metabolism and activity conditions can be met.

The invention discloses isoquinolin compounds shown as a formula I and salts thereof. The invention also discloses a preparation method for the compounds, which comprises the step of reacting compounds shown as IV under the action of a reducing agent in an alcohol solvent. The invention also discloses a medicine composition containing the compounds, and application of the compounds to preparing medicines for treating arrhythmia. The isoquinolin compounds and the salts thereof have good antiarrhythmic activity and small function of inhibiting myocardial contraction force.

The invention discloses a portable phono-electrocardio stethoscope and an application method thereof. Electrocardiogram instruments in the prior art are difficult to obtain heart sounds at the same time. According to the present invention, a shell rear cover is fixed to the top of a shell body, a stethoscope head cavity base is fixed to the shell rear cover, and a vibration film is fixed to the outer end of a cavity of the stethoscope head cavity base. A stethoscope head front cover is fixed with the stethoscope head cavity base. A sound guide tube is connected with the stethoscope head cavity base through an adapter. A microphone fixed in the sound guide tube is connected with a main control board. A first electrode plate and a second electrode plate are arranged in two placement holes in the stethoscope head front cover and below the vibrating film. The first electrode plate and the second electrode plate are both connected with the main control board. A shell base is fixed at the bottom of the shell body. A toggle switch is arranged on the shell base. The main control board is connected with a battery fixed on the inner wall of the shell body through the toggle switch. The two electrode plates are used for conducting electrocardio measurement, thereby improving flexibility. The microphone converts myocardial contraction, valve opening and closing, etc., fed back by the vibration film into electric signals, so that the phono-electrocardio combined analysis is more scientific.

Method and apparatus for the non-invasive detection of certain breathing conditions, certain sleep disordered breathing conditions, or assessment of the person's myocardial contractility and its dynamic changes, comprising steps of: determining the sleep or wake status of a person, monitoring circulatory pulse waveforms and amplitude normalized pulse wave systolic upstrokes recorded from a person's body and determining at least one index of the upstroke to characterize the strength of the contraction of the heart during the systolic upstroke during a series of heart beats relating to a breathing cycle or an absent anticipated breathing cycle of the patient, and determining that a certain change in a breathing condition, a sleep disordered breathing condition, or assessment of the person's myocardial contractility and its dynamic changes, has occurred when a specific change in the sleep disordered breathing analysis, and the at least one index of the upstroke has been detected.

The invention discloses a medicine formula for treating arrhythmia and cardiac postoperative recovery thereof, which comprises ginseng, astragalus membranaceus, ophiopogon root, asparagus cochinchinensis, pericarpium citri reticulatae, platycodon grandiflorum, polygonatum kingianum, pseudo-ginseng, rhizoma nardostachyos, radix bupleuri, prepared rehmannia root, tuber fleeceflower stem, liquorice and the like, all the medicines act together, and the medicine formula has the effects of clearing and activating the channels and collaterals, promoting blood circulation to remove blood stasis, reinforcing qi and nourishing yin, relieving palpitation and restoring pulse and the like, and can tonify qi and blood, improve microcirculation and promote the recovery of heart diseases. The traditional Chinese medicine composition can effectively treat palpitation, shortness of breath, weakness, dizziness, palpitation, chest distress, chest pain and other symptoms caused by heart vessel stasis, can be suitable for treatment of arrhythmia including ventricular premature beat and atrial premature beat, can also be used for rapid recovery after heart surgery (such as heart stent surgery and the like), and is remarkable in curative effect.

The invention discloses a valve prosthesis device implanted into a heart. The valve prosthesis comprises a valve main body and a ventricular volume reduction part, wherein the ventricular volume reduction part is fixed to the valve main body through a connecting part; and the ventricular volume reduction part is arranged in a manner that an isolation cavity for reducing the ventricular volume is formed between the ventricular volume reduction part and the inner wall of a cardiac apex. The valve prosthesis device can be used for replacing a native valve and treating mitral valve regurgitation caused by atrioventricular valve lesions, meanwhile, the ventricular volume reduction part is used for separating one part of the left ventricle through the isolation cavity formed between the ventricular volume reduction part and the inner wall of the cardiac apex, so that the left ventricular volume is restored to the normal size as much as possible, the left ventricular wall tension is reduced,myocardial oxygen consumption is reduced, myocardial contractility is enhanced, and cardiac function is improved; therefore, the valve prosthesis device can be used for treating mitral regurgitation and left ventricular enlargement caused by mitral regurgitation at the same time, heart failure is improved, and important clinical significance is achieved.

The invention discloses an application of thrombin aPC in drugs for prevention and treatment of diabetic cardiomyopathy induced by streptozotocin. The thrombin aPC can stabilize the expression of YB1by inhibiting ubiquitination of a cardiac muscle cell YB1 in a hyperglycemic state, so as to alleviate cardiomyocyte hypertrophy and fibrosis. The therapeutic study results indicate that the thrombinaPC has significant curative effects of alleviating cardiomyocyte hypertrophy and fibrosis, improving myocardial contractile functions and increasing ejection fraction.

Quantitatively diagnosing ischemia by non-invasively sensing mechanical vibrations from mechanical contraction of a ventricle to measure a time duration of an isovolumetric contraction and a peak endocardial acceleration (PEA) of the heart during the IVCT and calculating a myocardial contractility index (MCI) of the subject, for example MCI=PEA / IVCT. Comparing the MCI of the subject during the sensing period to a baseline MCI which is defined as the baseline MCI of the subject or a representative value of the baseline MCI of a population of subjects less a predetermined value, and then determining by a processor whether the MCI of the subject declined during the sensing period by at least a predetermined amount relative to the baseline MCI. Also allows determination of an amount of viable myocardium, existence of total occlusion of a coronary artery, myocardial infarction and whether thrombolysis has been effective so as to be discontinued.

An apparatus for improving the cardiac function and cardiac output of a patient comprises a waveform generator that generates alternating voltage pulses, a controller to control the timing of the pulses, and electrodes that deliver the alternating voltage pulses to the patient's body. The alternating voltage pulses induce a field of alternating current pulses within the patient's body. As the pulses pass through a cardiac ventricle (or atrium), they increase the concentration of Ca2+ at the appropriate cardiomyocyte sites, and thereby increase the strength and duration of the ventricular (or atrial) contractions. In alternative embodiments, the electric field may be used to strengthen the contractions of non-cardiac muscle (e.g., skeletal muscle).

An implantable medical device applies an electric signal over two electrodes and measures the resulting electric signal over a candidate pair of neighboring electrodes on a lead for a first heart ventricle or over a candidate electrode of the lead and a case electrode. An impedance signal is determined for each candidate pair or electrode based on the applied signal and the measured resulting signal. A time difference between start of contraction in a second ventricle and the timing of local myocardial contraction as identified from the impedance signal at the site of the candidate pair or electrode is determined for each candidate pair or electrode. An optimal pacing electrode is selected to correspond to one of the electrodes of the candidate pair having the largest time difference or the candidate electrode having largest time difference.

The invention provides a formula for improving cardiac myocardial cell functions and enhancing blood supply and oxygen supply of cardiac myocardial cells and a preparation process, and relates to the technical field of medicine and health care. The formula for improving the cardiac myocardial cell functions and enhancing the blood supply and oxygen supply of the cardiac myocardial cells comprises vitamin E, Cyclic adenosine monophosphate, isosorbide mononitrate, nitroglycerin, D-ribose, myocardial peptide powder, yak bone marrow peptide powder, compound amino acid, taurine and citric acid. A composition prepared by the invention can dilate blood vessels, enhance myocardial contractility, accelerate metabolism and improve myocardial nutrition, is very helpful for heart maintenance, can improve ventricular diastolic function and enhance blood supply and oxygen supply ability, and improves the practicability of the composition. The medicine residues are collected and treated, the effect of using medicine liquid and tablets at the same time is achieved, waste of resources can be reduced, meanwhile, the preparation technology is simple, and economic benefits are high.

The invention discloses a portable cardiac sound and electrocardiogram monitoring integration system. An existing electrocardiogram relevant instrument is difficult to simultaneously obtain cardiac sound data. The shell of the portable cardiac sound and electrocardiogram monitoring integration system is fixedly provided with a first electrode, a second electrode, a third electrode, a connection hole and a charging hole; a data head is electrically connected with the connection hole; a first conductor is used for connecting the data head and a cardiac sound electrode patch; an energy converter is electrically connected with the connection hole; and the data head, a second conductor, a connection end head, a connection button, a base plate and an electrode sheet are electrically connected in sequence. The electrode sheet is attracted to clothes through cooperation of a first magnet and a second magnet so as to guarantee that the position of the electrode sheet is accurate and stable, and a monitoring effect is better; the cardiac sound electrode patch is pasted to the skin surface of the heart area, the energy converter converts mechanical vibration, including myocardial contraction, valve starting and closing and the like, into an electric signal, and the electric signal is recorded to form a cardiac sound diagram; and the electrode patch is spliced to four skin areas, cardiac sound analysis and electrocardiogram activity analysis are favorable for reflecting the specific state of the heart, and data analysis is more scientific and comprehensive.